MK0767 in Type 2 Diabetes (0767-012)

Phase 2

Terminated

• Conditions: Type 2 Diabetes Mellitus

• Registration Number: NCT00543556
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767. This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2001-10
• Primary Completion: 2003-11
• Study Completion: 2003-11
• Study First Submitted: 2007-10-05
• Study First Submitted QC: 2007-10-12
• Study First Posted: 2007-10-15
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-12
• Last Update Posted: 2015-06-15

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 514

Inclusion Criteria

• Type 2 Diabetes Mellitus patients between the ages of 21 and 75 inclusive
• Patient is willing to discontinue current therapy for the duration of the study
• Patient is not a heavy drinker

Read More

Exclusion Criteria

• Patient has a history of Type 1 diabetes and/or ketoacidosis
• Patient has severe diabetic retinopathy, or nephropathy, or neuropath
• Patient has has anti-hyperglycemic therapy including insulin, or rosiglitazone and pioglitazone or 2 or more oral agents in combination within 8 weeks prior to visit 1
• Patient has a history of, allergy to, intolerance or hypersensitive to troglitazone, rosiglitazone, or pioglitazone including history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL